Skip to content

EVEN - Effects of VR on Empathy for Nature in Patients with Psychosis and Depressive Disorders

EVEN - Effects of VR on Empathy for Nature in Patients with Psychosis and Depressive Disorders / Effekte Von Virtueller Realität (VR) Auf Naturverbundenheit Und Empathie in Patient:innen Mit Psychotischen Und Depressiven Erkrankungen

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06446856
Acronym
EVEN
Enrollment
60
Registered
2024-06-06
Start date
2024-05-27
Completion date
2024-06-30
Last updated
2024-09-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depressive Disorder, Healthy Control, Schizophrenia

Brief summary

Study group: Experimental study to evaluate empathy, compassion, and nature connectedness before and after an immersive virtual reality experience in patients with depressive disorder, patients with psychotic disorder and healthy control subjects (subjects between 18 and 65 years of age). Primary hypothesis: The increase in nature connectedness explored by virtual body ownership of a tree in VR differs depending on the health condition (schizophrenia, depression, healthy controls).

Interventions

DEVICEVR application

The VR application consists of a software (Tree) developed as part of a research project at MIT and legally acquired via the HTC store Viveport. Duration of the VR application: approx. 5 min.

Sponsors

Universität Potsdam, Department Erziehungswissenschaft, Arbeitsbereich Schulbezogene Medienbildung
CollaboratorUNKNOWN
Charite University, Berlin, Germany
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* age: 18-65 years * Inpatients and outpatients treated at the Psychiatric University Clinic of the Charité at St. Hedwig Hospital * diagnosis of depressive disorder (ICD-10: F32.X, F33.X) or diagnosis of schizophrenia (F20.X) or healthy controls without psychiatric diagnosis * able to provide written informed consent

Exclusion criteria

* Acute suicidality or danger to others * Primarily treatment-requiring eating disorder * Acute dermatological condition affecting the hands that can distort skin conductivity measurements * Control group: psychiatric or psychosomatic pre-diagnoses (except for the psychiatric active control group), other exclusion diagnoses corresponding to the patient group

Design outcomes

Primary

MeasureTime frameDescription
Nature ConnectednessFor all groups pre and directly post VR exposureMeasurement of Nature Connectedness as a state with the Inclusion of Nature in Self (INS)-Questionnaire (Kleespies et al., 2021), pre and post VR exposure.

Secondary

MeasureTime frameDescription
symptom burdenFor the VR study group (patients with depressive disorder) and VR active control group (patients with psychotic disorder) pre and post VR exposure (within the same session of 1 hour)Measured with the PANAS (see above) and with the Visual Analogue Scale (0-10) measuring the burden of the 3 main symptoms, previously specified during assessment of symptom severity (PANSS; (Kay et al., 1987) and Beck Depression Inventory (BDI, Beck et al., 1961))
Spiritualitypre VR exposure for all groupsEvaluation of spirituality using the 4-item short version of the questionnaire Transpersonales Vertrauen (Hampel et al., 2019) pre VR exposure.
Presence in VRpost VR exposure for all groups (within the same session of 1 hour)Scale according to Ahn et al. (Ahn et al., 2016), adapted from the Spatial Presence scale by Bailenson et al. (2005) - own German translation adapted to the virtual Amazon forest area (Spangenberger et al., 2024)
Virtual Reality Simulator Sicknesspost VR exposure for all groups (within the same session of 1 hour)Cyber Sickness as a potential side effect of VR, measured with the Virtual Reality Sickness Questionnaire (Kim et al., 2018)
Explorative evaluation of electrodermal activity (EDA)during (approx. 5 minutes) VR exposureExplorative evaluation of electrodermal activity (EDA), e.g., skin conductance level (SCL) and skin conductance responses (SCR) in micro siemens during VR exposure
EmpathyFor all groups pre and directly post VR exposure (within the same session of 1 hour)Evaluation of empathy with the Multifaceted Empathy Test (MET; (Dziobek et al., 2008) pre and post VR exposure
CompassionFor all groups pre and directly post VR exposure (within the same session of 1 hour)Evaluation of Compassion (state compassion) pre and post VR exposure with the Positive and Negative Affect Schedule (PANAS) and five integrated items measuring compassion based on Pfattheicher et al., 2015.
Embodiment - Feeling of virtual body ownershippost VR exposure for all groups (within the same session of 1 hour)Evaluation with a subscale of the Embodiment scale by Ahn et al. (2016) adapted from Slater et al. (2010)

Other

MeasureTime frameDescription
symptom severity - psychotic symptomsFor the VR study group (patients with depressive disorder) and VR active control group (patients with psychotic disorder) pre VR exposure (within the same session of 1 hour)Assessment of symptom severity with the Positive and Negative Syndrome Scale (PANSS; Kay et al., 1987)
symptom severity - depressive symptomsFor the VR study group (patients with depressive disorder) and VR active control group (patients with psychotic disorder) pre VR exposure (within the same session of 1 hour)Assessment of symptom severity with the Beck Depression Inventory (BDI; Beck et al., 1961)
demographic variablespre VR exposure for all groupsacquisition of demographic data
comorbiditiespre VR exposure for all groupsacquisition of psychiatric comorbidities and physical illnesses

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 25, 2026